| Filed On | Filing |
|---|---|
| 21 May 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On May 19, 2026, in connection with Mr. Silver’s new role as the Company’s interim chief financial officer and principal financial officer, the Committee approved a monthly interim assignment fee of $12,250 (the “Interim CFO Assignment F... |
| 11 Sep 2023 |
8-K/A: Financial Statements and Exhibits
To the Shareholders and the Board of Directors of VectivBio Holding AG |
| 24 Jun 2021 |
8-K/A: Departure/Election of Directors or Officers; Compensation
This Second Amended & Restated Executive Severance Agreement (this “Agreement”) is made as of the day of June 22, 2021 (the “Effective Date”) by and between Ironwood Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Thom... |
| 15 Mar 2021 |
8-K/A: Departure/Election of Directors or Officers; Compensation
In connection with Mr. McCourt becoming the Company’s interim Chief Executive Officer, the Board approved an annual base salary of $775,000 (the “Interim CEO Salary”) and target bonus of 75% of the Interim CEO Salary for Mr. McCourt. Mr.... |
| 03 May 2019 |
8-K/A: Departure/Election of Directors or Officers; Compensation
As previously reported, on April 1, 2019, the Company completed the separation of its soluble guanylate cyclase business, and certain other assets and liabilities, into a separate, independent publicly traded company. This separation was... |
| 28 Mar 2019 |
8-K/A: Departure/Election of Directors or Officers; Compensation
The completion of the Separation is currently expected to occur on April 1, 2019 (the “Separation Date”). At that time, the New Ironwood Directors (as defined in the January 24 Report) are expected to be appointed to the Board and the De... |
Loading...